Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews the literature on the off-label use of botulinum toxin for dermatological conditions, highlighting its potential effectiveness in treating rosacea, anal fissures, Raynaud phenomenon, hypertrophic scars, keloids, and hidradenitis suppurativa.

This article reviews the role of adult stem cells in tissue homeostasis and wound repair, focusing on their regulation within the murine hair follicle's specialized niche, but it presents no new findings.

This review found that, among 103 patients treated off-label with abrocitinib for conditions beyond atopic dermatitis, favorable clinical outcomes were reported for most cases, except one isolated case involving erythematotelangiectatic rosacea.

In this study, PKC ε transgenic mice exposed to ultraviolet radiation showed increased hair follicle stem cell frequency and altered gene expression compared to wild-type mice, suggesting a potential role in skin cancer susceptibility.

This systematic review assessed the off-label use of topical Ruxolitinib cream for various skin conditions and found it effective for lichenoid and granulomatous dermatoses, though results for alopecia areata were inconsistent. The authors indicate that further research is warranted to confirm these findings.

This review focuses on the pharmacological properties, indications, contraindications, and safety profile of bicalutamide, a non-steroidal androgen receptor antagonist, in dermatological research, particularly its off-label use for improving female pattern hair loss as measured by Sinclair grading.

This retrospective study at the University Clinical Centre in Gdańsk reported that 77.9% of patients with alopecia areata were treated with off-label pharmacotherapy, predominantly glucocorticosteroids, highlighting a reliance on these therapies in European clinical practice.

This review discusses the off-label use of drugs and emphasizes the need for standardized guidelines due to varying international regulations and safety concerns, but reports no new clinical results.

This study found that combined therapy with cetirizine and topical steroids stabilized inflammation in most patients with lichen planus pilaris, though one patient experienced cardiac arrhythmia.

This study found that the HairComb algorithm achieved high accuracy in quantifying percentage hair loss across various types of alopecia, suggesting its potential for standardized automated assessments.

Abatacept may help some people with alopecia areata regrow hair.

This study found that nestin-driven GFP labels blood vessels originating from hair follicles in mice, which could be used to study early events in skin angiogenesis and for antiangiogenesis drug screening.

In an open-label clinical trial, this study found that applying Narasimham Hair Oil thrice weekly for 8 weeks significantly improved hair density, thickness, and scalp health among participants with hair thinning, with benefits persisting after treatment, and 95% reporting user satisfaction without adverse effects.

This open-label study found that combining exosome therapy with microneedling significantly improved hair density and patient satisfaction for male patients with mild to moderate androgenetic alopecia, with most reporting noticeable improvements and only mild, transient side effects after 12 months.

This review examines the off-label use of low-dose oral minoxidil for treating alopecia, comparing it to topical minoxidil and discussing potential risks, benefits, and side effects, as well as nursing considerations for patient care.

The FDA approved using Cialis with Proscar for better treatment options.

This review examines existing research and clinical trials on the use of dupilumab for various skin, respiratory, and gastrointestinal disorders, but it reports no new clinical findings.

This review suggests that low-dose oral minoxidil may enhance hair density in certain nonandrogenetic alopecias, but highlights the need for controlled trials due to mixed and limited evidence.

In this study, researchers reported significant improvement in sexual function and related symptoms for four patients using off-label flibanserin, suggesting potential broader applications beyond premenopausal women with hypoactive sexual desire disorder.

This randomized clinical trial observed that Facia Men’s capsule significantly reduced hair shedding in men with androgenetic alopecia over 12 weeks without affecting renal or liver function, though a small change in blood glucose suggests monitoring metabolic health.

This study found that Facia Men’s capsule significantly reduced hair shedding in men with androgenetic alopecia over 12 weeks, without notable renal or liver safety concerns.

This review highlights that deucravacitinib, a selective TYK2 inhibitor, shows promise as an effective treatment for psoriasis and other inflammatory skin diseases, though real-world evidence beyond psoriasis is still emerging.

This study discusses the use of low-dose oral minoxidil for hair loss, noting that while it is popular and considered safe, it can mimic Cantú syndrome effects such as hypertrichosis and pericardial effusion, necessitating careful monitoring and caution during prescription.

This consensus concluded that oral isotretinoin is highly effective for treating acne and some off-label conditions, with common adverse events being manageable and rare serious risks not contraindicating use.

This article notes the lack of physician-reported outcome studies supporting the efficacy of off-label spironolactone in treating female pattern hair loss, despite its common prescription alongside FDA-approved topical minoxidil.

In this study, ritlecitinib was generally well tolerated in pediatric alopecia areata patients aged 6 to <12 years, with no severe or serious adverse events reported, and the drug's pharmacokinetic parameters were successfully characterized.

This study found that 2% minoxidil led to moderate to dense hair growth in 80% of Middle-Eastern men treated for 48 weeks with early androgenic alopecia.

Low-dose oral minoxidil does not cause tachycardia in hair loss patients.

This study observed that photobiomodulation therapy may contribute to hair growth stability or improvement in individuals with darker skin types, without reported adverse events, though its findings are limited by a small sample size.

This study highlights the diverse prescribing and monitoring practices for low-dose oral minoxidil among dermatologists in the UK and Ireland, used widely for various hair loss conditions both as monotherapy and adjunctive therapy.